Pharmacokinetics of haloperidol: an update (Q33813315)

29 July 2017

1 reference

title

Pharmacokinetics of haloperidol: an update (English)

1 reference

29 July 2017

1 reference

ChEBI release 2020-05-28

1 reference

Kudo S

1

1 reference

PubMed ID

10628896

29 July 2017

Ishizaki T

series ordinal

2

1 reference

29 July 2017

1 December 1999

1 reference

Clinical Pharmacokinetics

29 July 2017

1 reference

29 July 2017

37

1 reference

29 July 2017

435-456

1 reference

29 July 2017

6

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-199937060-00001

29 July 2017

0 references

cites work

Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test

1 reference

12 December 2020

Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone

1 reference

12 December 2020

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

1 reference

12 December 2020

Clinically significant pharmacokinetic drug interactions with carbamazepine. An update

1 reference

12 December 2020

Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation

1 reference

12 December 2020

Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia

1 reference

12 December 2020

Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine

1 reference

12 December 2020

Stereospecific reduction of haloperidol in human tissues.

1 reference

12 December 2020

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

1 reference

12 December 2020

Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice

1 reference

12 December 2020

Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs.

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic interactions among haloperidol, carteolol hydrochloride and biperiden hydrochloride.

1 reference

12 December 2020

Metabolism of carteolol by cDNA-expressed human cytochrome P450.

1 reference

12 December 2020

Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation

1 reference

12 December 2020

Fluvoxamine-tricyclic antidepressant interaction

1 reference

12 December 2020

Subcellular fractionation of human liver

1 reference

12 December 2020

A comparative study of biliary and urinary 2-hydroxylated metabolites of [6,7-3H]17 alpha-ethynylestradiol in women

1 reference

12 December 2020

Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide*

1 reference

12 December 2020

Pharmacokinetics of haloperidol in psychotic patients

1 reference

12 December 2020

In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo

1 reference

12 December 2020

Effect of haloperidol and its metabolites on dopamine and noradrenaline uptake in rat brain slices

1 reference

12 December 2020

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

1 reference

12 December 2020

Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation

1 reference

12 December 2020

Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism

1 reference

12 December 2020

The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction

1 reference

12 December 2020

Metabolism of haloperidol: clinical implications and unanswered questions

1 reference

12 December 2020

Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients

1 reference

12 December 2020

1 reference

12 December 2020

Influence of Cigarette Smoking on Drug Metabolism in Man

1 reference

12 December 2020

Effects of carbamazepine on plasma haloperidol levels

1 reference

12 December 2020

Metabolism of haloperidol to pyridinium species in patients receiving high doses intravenously: is HPTP an intermediate?

1 reference

12 December 2020

Apparent interaction between nefazodone and cyclosporine

1 reference

12 December 2020

The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.

1 reference

12 December 2020

Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes.

1 reference

12 December 2020

Update on rifampin drug interactions. II.

1 reference

12 December 2020

Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol

1 reference

12 December 2020

Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive‐drug interactions with anticonvulsants and antibiotics

1 reference

12 December 2020

Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

1 reference

12 December 2020

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects

1 reference

12 December 2020

Pharmacokinetic studies on haloperidol in man.

1 reference

12 December 2020

Increased carbamazepine plasma concentrations after fluoxetine coadministration

1 reference

12 December 2020

Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone

1 reference

12 December 2020

Effect of Carbamazepine on Ciclosporin Blood Level

1 reference

12 December 2020

Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms

1 reference

12 December 2020

Elevated levels of clozapine in serum after addition of fluvoxamine

1 reference

12 December 2020

Lamotrigine clinical pharmacokinetics

1 reference

12 December 2020

Mammalian carbonyl reductases

1 reference

12 December 2020

Nefazodone-induced carbamazepine toxicity

1 reference

12 December 2020

Haloperidol concentrations elevated in Chinese patients

1 reference

12 December 2020

Haloperidol kinetics after oral and intravenous doses

1 reference

12 December 2020

Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients

1 reference

12 December 2020

Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients

1 reference

12 December 2020

Low plasma reduced haloperidol/haloperidol ratios in Chinese patients

1 reference

12 December 2020

Distribution, excretion and metabolism of neuroleptics of the butyrophenone type. I. Excretion and metabolism of haloperidol and nine related butyrophenone-derivatives in the Wistar rat

1 reference

12 December 2020

In vitro forecasting of drugs that may interfere with codeine bioactivation

1 reference

12 December 2020

Serum haloperidol levels of schizophrenics receiving treatment for tuberculosis

1 reference

12 December 2020

Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia

1 reference

12 December 2020

Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients

1 reference

12 December 2020

Elimination half-life and bioavailability of haloperidol in schizophrenic patients

1 reference

12 December 2020

Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations

1 reference

12 December 2020

Intra- and interethnic variability in reduced haloperidol to haloperidol ratios

1 reference

12 December 2020

Substantial rise in sparteine metabolic ratio during haloperidol treatment

1 reference

12 December 2020

Blood levels of haloperidol and clinical outcome in schizophrenia

1 reference

12 December 2020

N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors

1 reference

12 December 2020

A gas chromatographic method for determining haloperidol. A sensitive procedure for studying serum concentration and pharmacokinetics of haloperidol in patients

1 reference

12 December 2020

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

1 reference

12 December 2020

Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man

1 reference

12 December 2020

Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia

1 reference

12 December 2020

Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam

1 reference

12 December 2020

Reduced haloperidol in the post-mortem brains of haloperidol-treated patients

1 reference

12 December 2020

P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients

1 reference

12 December 2020

Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic

1 reference

12 December 2020

Use of antisera in the isolation of human specific conjugates of haloperidol

1 reference

12 December 2020

Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics.

1 reference

12 December 2020

Acute effects of lamotrigine (BW430C) in persons with epilepsy

1 reference

12 December 2020

Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole

1 reference

12 December 2020

Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.

1 reference

12 December 2020

Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients

1 reference

12 December 2020

Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism

1 reference

12 December 2020

Inhibition by fluoxetine of cytochrome P450 2D6 activity.

1 reference

12 December 2020

Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes

1 reference

12 December 2020

Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid

1 reference

12 December 2020

Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms?

1 reference

12 December 2020

A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia

1 reference

12 December 2020

Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients

1 reference

12 December 2020

Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations

1 reference

12 December 2020

Effect of carbamazepine on neuroleptic plasma levels and efficacy

1 reference

12 December 2020

Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction

1 reference

12 December 2020

Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates

1 reference

12 December 2020

Toxic Interaction Between Fluvoxamine and Sustained Release Theophylline in an 11-Year-Old Boy

1 reference

12 December 2020

Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications.

1 reference

12 December 2020

Plasma level profile of haloperidol in man following intramuscular administration

1 reference

12 December 2020

Smoking and drug metabolism

1 reference

12 December 2020

Elevation of plasma concentrations of haloperidol after the addition of fluoxetine

1 reference

12 December 2020

Purification and properties of an NADPH-dependent carbonyl reductase from human brain. Relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase

1 reference

12 December 2020

Clinical pharmacokinetics of nefazodone

1 reference

12 December 2020

Metabolism of the antianxiety drug buspirone in human subjects

1 reference

12 December 2020

D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate

1 reference

12 December 2020

Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine

1 reference

12 December 2020

A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia.

1 reference

12 December 2020

Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin.

1 reference

12 December 2020

In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine

1 reference

12 December 2020

Isolation and Identification of a Metabolite of Haloperidol

1 reference

12 December 2020

Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment.

1 reference

12 December 2020

Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components

1 reference

12 December 2020

Total and free plasma neuroleptic levels in schizophrenic patients

1 reference

12 December 2020

Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole

1 reference

12 December 2020

Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia

1 reference

12 December 2020

Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol

1 reference

12 December 2020

The erythromycin breath test predicts the clearance of midazolam.

1 reference

12 December 2020

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

1 reference

12 December 2020

Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese

1 reference

12 December 2020

Commentary: a physiological approach to hepatic drug clearance

1 reference

12 December 2020

Inhibitors of imipramine metabolism by human liver microsomes

1 reference

12 December 2020

The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia

1 reference

12 December 2020

Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report

1 reference

12 December 2020

Pharmacokinetic Drug Interactions with Oral Contraceptives

1 reference

12 December 2020

Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs

1 reference

12 December 2020

Haloperidol reduction can be assayed in human red blood cells

1 reference

12 December 2020

Interaction between fluvoxamine and imipramine/desipramine in four patients

1 reference

12 December 2020

Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine.

1 reference

12 December 2020

Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins.

1 reference

12 December 2020

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

1 reference

12 December 2020

Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy

1 reference

12 December 2020

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

1 reference

12 December 2020

Antipsychotic drug use in the United States, 1976-1985.

1 reference

12 December 2020

The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone

1 reference

12 December 2020

The Role of Active Metabolites in Drug Toxicity

1 reference

12 December 2020

Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6

1 reference

12 December 2020

Haloperidol plasma concentrations in Taiwanese psychiatric patients.

1 reference

12 December 2020

Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects

1 reference

12 December 2020

Basic principles of rapid neuroleptization

1 reference

12 December 2020

Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications

1 reference

12 December 2020

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

1 reference

12 December 2020

Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers.

1 reference

12 December 2020

Antischizophrenic drugs: Differential plasma protein binding and therapeutic activity

1 reference

12 December 2020

A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine

1 reference

12 December 2020

Drug metabolism by cytochromes P450 in the liver and small bowel.

1 reference

12 December 2020

In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase

1 reference

12 December 2020

Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder

1 reference

12 December 2020

Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair

1 reference

12 December 2020

Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation

1 reference

12 December 2020

Oxidation of quinidine by human liver cytochrome P-450

1 reference

12 December 2020

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.

1 reference

12 December 2020

Haloperidol reductase in human and guinea pig livers

1 reference

12 December 2020

Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19.

1 reference

12 December 2020

Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis

1 reference

12 December 2020

Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol

1 reference

12 December 2020

[Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate]

1 reference

12 December 2020

Alprazolam is another substrate for human cytochrome P450-3A isoforms.

1 reference

12 December 2020

In vitro methods for assessing human hepatic drug metabolism: their use in drug development

1 reference

12 December 2020

Coadministration of fluvoxamine increases serum concentrations of haloperidol

1 reference

12 December 2020

Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam

1 reference

12 December 2020

Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers

1 reference

12 December 2020

Protein Binding and Kinetics of Drugs in Liver Diseases

1 reference

12 December 2020

Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients

1 reference

12 December 2020

Valproate for epilepsy in renal transplant recipients receiving cyclosporine

1 reference

12 December 2020

Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies

1 reference

12 December 2020

Effect of anticonvulsants on plasma haloperidol and thioridazine levels

1 reference

12 December 2020

Interaction between carbamazepine and fluvoxamine

1 reference

12 December 2020

Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite

1 reference

12 December 2020

Interconversion between haloperidol and reduced haloperidol in healthy volunteers

1 reference

12 December 2020

Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450

1 reference

12 December 2020

Potential metabolic bioactivation pathways involving cyclic tertiary amines and azaarenes.

1 reference

12 December 2020

Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol

1 reference

12 December 2020

Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients

1 reference

12 December 2020

Interactions between carbamazepine and birth control pills

1 reference

12 December 2020

Total and free serum haloperidol levels in schizophrenic patients and the effect of age thioridazine and fatty acid on haloperidol-serum protein binding in vitro

1 reference

12 December 2020

Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam

1 reference

12 December 2020

[Possible interaction between theophylline and fluvoxamine]

1 reference

12 December 2020

Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia

1 reference

12 December 2020

Formation of pyridinium species of haloperidol in human liver and brain

1 reference

12 December 2020

Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients

1 reference

12 December 2020

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

1 reference

12 December 2020

Identification of 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice

1 reference

12 December 2020

Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications

1 reference

12 December 2020

Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes.

1 reference

12 December 2020

Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants

1 reference

12 December 2020

Haloperidol plasma levels and clinical response: a therapeutic window relationship

1 reference

12 December 2020

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

1 reference

12 December 2020

An open trial of buspirone added to neuroleptics in schizophrenic patients.

1 reference

12 December 2020

Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction?

1 reference

12 December 2020

Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol

1 reference

12 December 2020

Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype

1 reference

12 December 2020

Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics

1 reference

12 December 2020

Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients

1 reference

12 December 2020

Grapefruit juice-drug interactions

1 reference

12 December 2020

Pharmacokinetics of haloperidol

1 reference

12 December 2020

Interconversion between haloperidol and reduced haloperidol in humans

1 reference

12 December 2020

Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.

1 reference

12 December 2020

Interaction of citrus juices with pranidipine, a new 1,4-dihydropyridine calcium antagonist, in healthy subjects

1 reference

12 December 2020

Reduced haloperidol/haloperidol ratios in plasma: polymorphism in Japanese psychiatric patients.

1 reference

12 December 2020

Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients

1 reference

12 December 2020

Measurement of haloperidol reductase activity in red blood cells and reduced haloperidol/haloperidol ratios in plasma in oriental psychiatric patients

1 reference

12 December 2020

A fluvoxamine-caffeine interaction study

1 reference

12 December 2020

The erythromycin breath test as a predictor of cyclosporine blood levels.

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors

1 reference

12 December 2020

Therapeutic drug monitoring of psychotropic drugs in children

1 reference

12 December 2020

Effect of pindolol administration on serum levels of thioridazine, haloperidol, phenytoin, and phenobarbital.

1 reference

12 December 2020

The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.

1 reference

12 December 2020

Altered Hepatic Blood Flow and Drug Disposition1

1 reference

12 December 2020

In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol.

1 reference

12 December 2020

Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem

1 reference

12 December 2020

Lymphocyte microsomal epoxide hydrolase in patients on carbamazepine therapy

1 reference

12 December 2020

Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations

1 reference

12 December 2020

Effects of a quaternary pyridinium metabolite of haloperidol (HP+) on the viability and catecholamine levels of cultured PC12 cells.

1 reference

12 December 2020

Fluoxetine impairs clearance of alprazolam but not of clonazepam

1 reference

12 December 2020

The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids

1 reference

12 December 2020

The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients

1 reference

12 December 2020

10.2165/00003088-199937060-00001

Identifiers

DOI

1 reference

PubMed ID

10628896

Dimensions Publication ID

29 July 2017

0 references

1 reference

PubMed ID

10628896